Jan 28, 2025 · Chronic kidney disease is a common complication for people living with type 2 diabetes. Diabetes is the leading cause of kidney failure, which is one of the leading causes of …

3 days ago · FDA approves Ozempic ® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic …

May 24, 2024 · Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease.

Jan 28, 2025 · The F.D.A. based its decision to expand the approved uses of Ozempic on research showing that people with Type 2 diabetes and chronic kidney disease who took the …

Jan 28, 2025 · chronic kidney disease . Plainsboro, N.J., January 28, 2025 – Novo Nordisk today announced . that the U.S. Food and Drug Administration (FDA) has approved Ozempic® to …

2 days ago · The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage …

Mar 8, 2024 · People with type 2 diabetes and chronic kidney disease (CKD) who took Ozempic (semaglutide) slowed the progression of kidney disease by 24% and cut their risk of death …

May 24, 2024 · Semaglutide, the compound in the blockbuster drugs Ozempic and Wegovy, dramatically reduced the risk of kidney complications, heart issues and death in people with …

Jan 30, 2025 · The Food and Drug Administration (FDA) on Tuesday approved Ozempic (semaglutide) to reduce the risk of complications and death in adults with both type 2 diabetes …

Jan 28, 2025 · Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.